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Introduction
Over the past few decades medicine has been changing
rapidly. For a long time the medical field relied primarily
on evidence-based medicine, which focused on data from
clinical trials [1]. In contrast, the medicine of the future
will be based on presymptomatic indicators, a wellness-
maintenance system, several measurements – including
different numbers of ‘OMICs’, e.g. genomics, proteomics
– individual-centric needs, the social networking of
patients, and the genotype and phenotype of diseases [1].
In the 21st century, the terms personalized medicine,
precise medicine, genomic medicine and even personal
radiology have been used frequently [2]. Personalized
medicine ensures that patients receive the right treat-
ment at the right dose at the right time, with minimum
adverse consequences and maximum efficacy [3]. As
personalized medicine becomes more practical, image-
guided biopsies will be integral for facilitating predictive
and pharmacodynamic molecular pathology. Meanwhile,
imaging has an important role in precise medicine [3].
Progress in diagnostic procedures, genomics and pro-
teomics allows a window into subcellular mechanisms [3].
Personalized medicine ensures that clinical decisions
are made according to a patient’s molecular profile.
Numerous crucial markers of diseases have already been
accepted into standard practice [4]. For example, mole-
cular imaging with a tissue biomarker will help in the
discovery of novel drugs and also in predictive biopsies
[4,5]. Furthermore, response to therapy has a multi-
faceted link to genotype, dysregulation of signalling
conduits using gene expression, protein activity,
protein–protein interactions and disease phenotypic
traits. It is possible to gather these data with molecular
imaging as well as with other established techniques, but
imaging is problematic with thousands of low-specific
markers [6].
Regarding the ‘holy trinity’ consisting of new technolo-
gies, new analytical tools and systems biology, molecular
imaging requires advances in hardware and software to
perform more complex mathematical and computational
analyses [7].
Systems biology, health and disease
Systems biology, with its holistic approach to discovering
important principles in biology (complex system) and the
enabling technologies in genomics, proteomics, single-
cell analysis, microfluidics and computational strategies,
empowers a comprehensive approach to medicine [8,9].
Systems medicine originates in the perception that dis-
ease develops as a consequence of one or more disease-
perturbed networks and these networks are dynamically
altered during the course of the disease [3,7].
There are several networks working in the context of an
individual’s body, such as genetic networks, molecular
networks, cellular networks and organ networks, which
must be considered to truly understand the systems view
of disease [7,9]. However, there are many diseases that,
despite having dissimilar forms of clinical manifestation,
form part of the same network. Indeed, with this
approach, the ‘diseasome’ has been introduced as the
network of human diseases that share common genetic
and molecular traits [8]. Exactly how the networks are
perturbed, and how these perturbed networks are dyna-
mically altered, can be better understood by using high-
throughput measurement technologies [3].
In addition, because of the dynamic situation of human
health and disease resulting from changing biologic net-
work architectures (genes, mRNAs, microRNAs, proteins
and metabolites) and also nodal elements, it is not
enough to have a static image of the system. Rather, it is
necessary to have a dynamic model, as can be achieved
with molecular imaging modalities, that captures the
development of the biological complexity in healthy and
unhealthy conditions before and after therapeutic inter-
vention [8]. Labelled agents that are particular for the
biologic processes could be applied for molecular imaging
even before symptoms develop [8].
General picture of P4 medicine
Medicine is now experiencing a major revolution that will
transform the nature of healthcare from a reactive to a
proactive approach [9–11]. In the next few years, it will
progressively transition to personalized, predictive,
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preventive and participatory medicine (P4 medicine)
[12,13]. The revolution will be catalysed by the advances
made in the basic scientific fields – such as complete
sequencing of the human genome, the progress in ima-
ging modalities and also the application of concepts of
engineering physics (such as scale-free networks and
complex systems) [8].
This revolutionary concept of P4 medicine was devel-
oped by David Galas and Leroy Hood from the Institute
for Systems Biology in Seattle [8], at which molecular
imaging plays an important role [14]. P4 medicine, as the
clinical face of systems medicine, which is a part of sys-
tems biology, has two main goals: to quantify wellness
and to demystify disease [9,15].
Impact of P4 medicine on the healthcare system
P4 medicine seems to present several advantages for the
healthcare system – for example, the possibility to obtain
and process billions of data sets for each individual, the
gathering and analysis of longitudinal data for each
individual, the stratification of patients into disease
groups and improvement of the drug development pro-
cess through the detection of new therapeutic target hubs
[8,16].
P4 challenges
Although technology has advanced significantly in the
last few decades, new advances are still needed for P4
medicine from bench to beach: (a) methods for sequen-
cing of personalized genomes; (b) microfluidic methods
and analysis of individual cells; (c) new computational
techniques for the development of predictive models of
the networks and dynamic interactions between the
biological components, which is based on the incorpora-
tion of high-throughput OMIC information (tran-
scriptomics, proteomics, metabolomics, lipidomics, etc.);
(d) teaching patients and physicians about P4 medicine;
and (e) new molecular imaging techniques. Although
technology is developing quickly, integrating such
acquired data with all other measurement data is a con-
siderable challenge.
P4 medicine in the context of molecular imaging
Personalized: P4 medicine will be ‘personalized’ as it will
be based on the genetic and epigenetic data of each
individual. Personalized or precision medicine can help
in data mining of quantitative anatomy and biology, in
targeted imaging/targeted therapy and also in the real-
time monitoring of treatment response.
Molecular imaging could provide particular molecular
profiles and aid in the selection of the most effective
treatment with the least toxicity on an individualized
basis [17–19]. Imaging agents that have both diagnostic
and therapeutic capabilities, or ‘theragnostics,’ would
likely be more cost-effective and popular [20]. The great
value of molecular imaging in personalized medicine is
based on its ability to integrate metabolic and physiologic
data with clinical phenotypes and prepare invaluable
information about treatments.
Predictive: on average, one human differs from another by
less than 1% of their genetic makeup. However, these
genetic variances cause physical dissimilarities, such as
the potential predisposition to different diseases [1].
Medicine will be ‘predictive’ as this personalized data
will permit medical practitioners to determine the risk for
specific diseases in each individual [19].
Imaging modalities will play a significant role as non-
invasive screening procedures that are both sensitive and
precise predictors of diseases [12]. Reports have revealed
that only PET affected the management decisions in
38% of cancer cases [21].
Preventive: medicine will be ‘preventive’ as the prediction
of risk will allow for the use of prophylactic procedures
(lifestyle or therapeutic) to lessen this risk. In this
context, it is widely accepted that molecular/genetic
screening as well as intervention (often guided by
imaging) is the most efficient approach to disease
management [19]. Theranostic agents can also be
implemented.
Participatory: it will be ‘participatory’ because most of
these prophylactic manipulations will necessitate the
contribution of the patient. This includes a range of
participatory activities, such as sharing data, educating
patients and physicians and also advising patients on
personal choices related to illness and well-being. The
growing use of social networks by patients, as well as the
activities of patients’ associations, are instances of parti-
cipatory actions [19].
Current NIH programmes on P4 with emphasis on
molecular imaging
P4 medicine is the future and has emphasized its role in
future directions [14,22]. There are various programmes
at the NIH that have been pursuing the concept of P4
medicine, including the current Molecular Libraries and
Imaging programme [23]. It works on small molecules
that can be useful as chemical probes to assess the
functions of genes, cells and biochemical pathways in
health and disease [24]. In this field, molecular imaging
tracers will have a great impact [24–26], and it was
mentioned 10 years ago that molecular imaging is one of
top 10 technologies that will change the world [27,28].
More examples of ongoing NIH programmes in this area
include the following: single cell analysis, metabolomics,
genotype-tissue expression, illuminating the druggable
genome and the big data to knowledge (BD2K) pro-
gramme [23].
Radiogenomics
In addition, translational bioinformatics is one of the
evolving fields that will help develop P4 medicine, as
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well as some terms such as personal genome, metagen-
ome, epigenome, genomics, pharmacogenomics, tran-
scriptomics and metabolomics pertaining to this branch of
science. These OMIC studies can be prepared by next-
generation sequencing, which is a high-throughput
technology based on informatics [double helix, Sanger
sequencing/genome project (SNP)].
Radiogenomics, another OMIC study, is the integration
of in-vivo imaging with large-scale gene expression pro-
files, which can show imaging heterogeneity mirroring
biological heterogeneity [29]. The fusion of imaging tools
with molecular techniques, such as functional genomic
assays, offers the potential for the rapid clinical transla-
tion of powerful high-throughput technology [29].
Radiogenomics can create imaging biomarkers that can
recognize the genomics of a disease, particularly cancer,
without the use of a biopsy [6,30]. Numerous techniques
are used to reveal correlations between MRI, CT and
PET imaging features and the genomics of disease, such
as large-scale MRI microRNA–mRNA correlative study
in glioblastoma [31,32], liver cancer genome from non-
invasive imaging features [33] and link image character-
istics of non-small-cell lung nodules in CT scans to
predict survival using gene expression data [29,34].
Recently, a radiogenomic study in incidentalomas was
conducted [35].
There has been vast improvement in the performance of
imaging modalities. For example, molecular imaging now
provides a functional and dynamic read-out of in-treat-
ments, from nanometre to entire body scale [4,36,37].
The multimodality imaging approach and the incorpora-
tion of multidimensional high-throughput ‘OMICS’
methods (accompanied by genetics/genomic data) would
bridge the gap between our knowledge of fundamental
mechanisms of disease processes and daily clinical prac-
tice [38]. Therefore, imaging doctors must learn genetic
pathways and therapeutically target points in a new
genetic world consisting of genetic data, clinical data and
imaging features.
Most significantly, the future of practice and research will
require network-connected and interdisciplinary teams of
image professionals, clinicians, specialists familiar with
the integrated analysis of both imaging and genetic data
types, as well as physiochemists and molecular biologists
[29]. In the future, the imaging doctor’s role will be that
of diagnostic data manager and coordinator, and not of
image interpreter.
Bringing new scientific issues into clinical practice
necessitates teamwork between academia and industry to
develop new agents and carry out translational research
[12]. Therefore, we should prepare a new training para-
digm for tomorrow’s colleagues to address the future
of biomedical imaging.
Conclusion
Medicine is now experiencing a major revolution that will
transform the nature of healthcare from reactive to
proactive. It will progressively transition to personalized,
predictive, preventive and participatory medicine (P4
medicine). In the meantime, ongoing technological
advances, especially in the field of molecular imaging,
and also interdisciplinary collaborations with various
branches of science are mandatory for the implementa-
tion of P4 medicine. New training paradigms are neces-
sary for tomorrow’s colleagues to establish the conceptual
bases and discuss the principal aspects of P4 medicine
in the framework of molecular imaging and determine
who will benefit from a deeper, more holistic view of
illness by integrating pathophysiology-based models with
emerging molecular mechanisms.
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